{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:10:57Z","timestamp":1786975857290,"version":"build-2736575974"},"reference-count":28,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2026,2,1]]},"abstract":"\n Importance<\/jats:title>\n Sleep disturbances are common in pregnancy and often treated with nonbenzodiazepine sedative hypnotics (Z-drugs). However, there is limited evidence on the fetal safety of Z-drugs.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate whether Z-drug exposure in the first trimester of pregnancy is associated with an increased risk of congenital malformations.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This US population-based cohort study evaluated health care utilization data from publicly insured beneficiaries in the Medicaid database (2000-2018) and commercially insured beneficiaries in the Merative MarketScan database (2003-2020). Participants were pregnant individuals and their liveborn infants, with maternal enrollment from 90 days before pregnancy to 30 days after delivery and infant enrollment for 90 days after birth unless death occurred sooner. Data analysis was performed from November 2023 to April 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n At least 1 dispensing of Z-drugs (zaleplon, eszopiclone, or zolpidem) in the first trimester of pregnancy compared with no dispensing.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Major congenital malformations were identified using linked maternal and infant claims. The risks of any major congenital malformation, organ-specific malformations, and individual malformations in pregnancies with Z-drug exposure in the first trimester were compared with the risks in unexposed pregnancies. Relative risks (RRs) and 95% CIs were estimated. Propensity score fine stratification weights were used to control for confounders.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 4\u202f281\u202f579 pregnancies were identified (mean [SD] maternal age at delivery, 25.2 [6.0] years in Medicaid and 31.6 [4.6] years in MarketScan). First-trimester Z-drug exposure was identified in 11\u202f652 (0.5%) of 2\u202f506\u202f106 pregnancies in Medicaid and 10\u202f862 (0.6%) of 1\u202f775\u202f473 pregnancies in MarketScan; 92.1% of exposed pregnancies had zolpidem exposure. The adjusted pooled RR for malformations overall was 1.01 (95% CI, 0.95-1.08). While adjusted pooled RRs were increased for abdominal wall defects (1.46; 95% CI, 0.89-2.38), tetralogy of Fallot (1.45; 95% CI, 0.86-2.46), and neural tube defects (1.62; 95% CI, 0.96-2.74), these associations were imprecisely estimated, driven by the Medicaid cohort and not replicated in the MarketScan cohort. Results were consistent across multiple sensitivity analyses.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n These findings suggest that Z-drug exposure in the first trimester of pregnancy is not associated with a meaningful elevation in the risk of congenital malformations overall, nor was there a consistent signal observed for organ-specific or uncommon, individual malformations examined.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2025.3874","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T16:00:29Z","timestamp":1766505629000},"page":"162","source":"Crossref","is-referenced-by-count":1,"title":["Z-Drug Use in the First Trimester of Pregnancy and Risk of Congenital Malformations"],"prefix":"10.1001","volume":"83","author":[{"given":"Kelly","family":"Fung","sequence":"first","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loreen","family":"Straub","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Bateman","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Hernandez-Diaz","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Brill","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmin","family":"Zhu","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee S.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Center for Women\u2019s Mental Health, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn J.","family":"Gray","sequence":"additional","affiliation":[{"name":"Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista F.","family":"Huybrechts","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"yoi250068r1","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.smrv.2017.06.005","article-title":"Sleep quality during pregnancy: a meta-analysis.","volume":"38","author":"Sedov","year":"2018","journal-title":"Sleep Med Rev"},{"issue":"1","key":"yoi250068r2","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.13207","article-title":"Insomnia symptoms during pregnancy: a meta-analysis.","volume":"30","author":"Sedov","year":"2021","journal-title":"J Sleep Res"},{"key":"yoi250068r3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jad.2020.01.140","article-title":"Mid-pregnancy insomnia is associated with concurrent and postpartum maternal anxiety and obsessive-compulsive symptoms: a prospective cohort study.","volume":"266","author":"Osnes","year":"2020","journal-title":"J Affect Disord"},{"issue":"9","key":"yoi250068r4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3390\/brainsci9090235","article-title":"Use of prescribed psychotropics during pregnancy: a systematic review of pregnancy, neonatal, and childhood outcomes.","volume":"9","author":"Creeley","year":"2019","journal-title":"Brain Sci"},{"key":"yoi250068r5","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2021.101436","article-title":"Sleep disturbances during pregnancy and adverse maternal and fetal outcomes: a systematic review and meta-analysis.","volume":"58","author":"Lu","year":"2021","journal-title":"Sleep Med Rev"},{"issue":"6","key":"yoi250068r6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/jdn.10118","article-title":"Sleep disorders during pregnancy and postpartum depression: a systematic review and meta-analysis.","volume":"81","author":"Maghami","year":"2021","journal-title":"Int J Dev Neurosci"},{"issue":"1","key":"yoi250068r7","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.chest.2019.09.026","article-title":"Sleep pharmacotherapy for common sleep disorders in pregnancy and lactation.","volume":"157","author":"Miller","year":"2020","journal-title":"Chest"},{"issue":"4","key":"yoi250068r8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.psym.2018.03.009","article-title":"Considerations in treating insomnia during pregnancy: a literature review.","volume":"59","author":"Chaudhry","year":"2018","journal-title":"Psychosomatics"},{"key":"yoi250068r9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2165\/00023210-200418001-00004","article-title":"The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents.","volume":"18","author":"Sanger","year":"2004","journal-title":"CNS Drugs"},{"issue":"11","key":"yoi250068r10","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1002\/pds.1457","article-title":"Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations.","volume":"16","author":"Wikner","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"yoi250068r11","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1097\/JCP.0b013e3182197055","article-title":"Are hypnotic benzodiazepine receptor agonists teratogenic in humans?","volume":"31","author":"Wikner","year":"2011","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"yoi250068r12","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.13958","article-title":"Maternal exposure to zolpidem and risk of specific birth defects.","volume":"33","author":"Howley","year":"2024","journal-title":"J Sleep Res"},{"issue":"6","key":"yoi250068r13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0100996","article-title":"First trimester exposure to anxiolytic and hypnotic drugs and the risks of major congenital anomalies: a United Kingdom population-based cohort study.","volume":"9","author":"Ban","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"yoi250068r14","doi-asserted-by":"publisher","first-page":"128","DOI":"10.2174\/157488611795684695","article-title":"High dose zolpidem induced fetal neural tube defects.","volume":"6","author":"Sharma","year":"2011","journal-title":"Curr Drug Saf"},{"issue":"6","key":"yoi250068r15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067405","article-title":"Harnessing the Medicaid Analytic eXtract (MAX) to evaluate medications in pregnancy: design considerations.","volume":"8","author":"Palmsten","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"yoi250068r16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/pds.3284","article-title":"Algorithms to estimate the beginning of pregnancy in administrative databases.","volume":"22","author":"Margulis","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"yoi250068r17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/EDE.0000000000001559","article-title":"Development and validation of algorithms to estimate live birth gestational age in Medicaid Analytic eXtract data.","volume":"34","author":"Zhu","year":"2023","journal-title":"Epidemiology"},{"issue":"4","key":"yoi250068r18","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/pds.4967","article-title":"Validation of algorithms to identify adverse perinatal outcomes in the Medicaid Analytic Extract database.","volume":"29","author":"He","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"102","key":"yoi250068r19","doi-asserted-by":"publisher","first-page":"n102","DOI":"10.1136\/bmj.n102","article-title":"Association of first trimester prescription opioid use with congenital malformations in the offspring: population based cohort study.","volume":"372","author":"Bateman","year":"2021","journal-title":"BMJ"},{"issue":"6","key":"yoi250068r20","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/pds.3627","article-title":"Validity of maternal and infant outcomes within nationwide Medicaid data.","volume":"23","author":"Palmsten","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"25","key":"yoi250068r22","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"issue":"2","key":"yoi250068r23","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/EDE.0000000000000595","article-title":"A propensity-score-based fine stratification approach for confounding adjustment when exposure is infrequent.","volume":"28","author":"Desai","year":"2017","journal-title":"Epidemiology"},{"issue":"2","key":"yoi250068r24","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/ppe.12733","article-title":"Drug-drug interactions in pregnancy: an important frontier for pharmacoepidemiology.","volume":"35","author":"Bateman","year":"2021","journal-title":"Paediatr Perinat Epidemiol"},{"issue":"25","key":"yoi250068r25","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1056\/NEJMoa1312828","article-title":"Antidepressant use in pregnancy and the risk of cardiac defects.","volume":"370","author":"Huybrechts","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"yoi250068r26","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3102\/10769986030003261","article-title":"Bias and efficiency of meta-analytic variance estimators in the random-effects model.","volume":"30","author":"Viechtbauer","year":"2005","journal-title":"J Educ Behav Stat"},{"issue":"2","key":"yoi250068r28","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/00031305.2016.1154108","article-title":"The ASA\u2019s statement on p-values: context, process, and purpose.","volume":"70","author":"Wasserstein","year":"2016","journal-title":"Am Stat"},{"key":"yoi250068r27","volume-title":"Modern Epidemiology","author":"Lash","year":"2021","edition":"4th ed"},{"key":"yoi250068r21","unstructured":"Economic Research Service, US Department of Agriculture. County-level data sets\u2014county-level data sets: download data. Accessed February 21, 2024. https:\/\/www.ers.usda.gov\/data-products\/county-level-data-sets\/download-data\/"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2843135\/jamapsychiatry_fung_2025_oi_250068_1768943462.92516.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T16:00:21Z","timestamp":1770220821000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2843135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.3874","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,1]]}}}